Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in persistent/chronic ITP (FIT-1)
NCT02076399Phase 3Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Jul 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of fostamatinib in immune thrombocytopenic purpura (ITP), sponsored by Rigel Pharmaceuticals, Inc.. Started Jul 2014; status: completed.
02
Drugs
fostamatinib
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT02076399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076399.